Roland Seifert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roland Seifert has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Katharina Wenzel-Seifert
6 shared publications- Andreas Gille
Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
4 shared publications Armin Buschauer
1 shared publicationHeinz H. Pertz
1 shared publicationHui-Yu Liu
Department of Pharmacology and Toxicology, The University of Kansas, Malott Hall, Room 5064, 1251 Wescoe Hall Drive, Lawrence 66045, USA
1 shared publicationMichael B. Doughty
From the Departments of ‡Pharmacology and Toxicology and §Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045-7582 and ¶Department of Chemistry and Physics, Southeastern Louisiana University, Hammond, Louisiana 70402-0878
1 shared publication
Latest Publications
- 4 December 2003
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 369 (2) , 141-150
Xanthine nucleotide-specific G-protein a-subunits: a novel approach for the analysis of G-protein-mediated signal transduction
- 4 December 2003
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 369 (2) , 141-150
Xanthine nucleotide-specific G-protein a-subunits: a novel approach for the analysis of G-protein-mediated signal transduction
- 27 October 2003
- Published by Elsevier in Life Sciences
- Vol. 74 (2-3) , 271-279
MANT-substituted guanine nucleotides: A novel class of potent adenylyl cyclase inhibitors
- 27 October 2003
- Published by Elsevier in Life Sciences
- Vol. 74 (2-3) , 271-279
MANT-substituted guanine nucleotides: A novel class of potent adenylyl cyclase inhibitors
- 1 September 2003
- Published by Elsevier in Life Sciences
- Vol. 73 (18) , 2263-2280
The human formyl peptide receptor as model system for constitutively active G-protein-coupled receptors
- 1 September 2003
- Published by Elsevier in Life Sciences
- Vol. 73 (18) , 2263-2280
The human formyl peptide receptor as model system for constitutively active G-protein-coupled receptors
- 14 August 2003
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 368 (3) , 210-215
Low-affinity interactions of BODIPY-FL-GTP?S and BODIPY-FL-GppNHp with Gi- and Gs-proteins
BODIPY-FL-guanosine 5'-[γ-thio]triphosphate (B-GTPγS) and BODIPY-FL-guanosine 5'-[β,γ-imido]triphosphate (B-GppNHp) induce fluorescence changes upon binding to purified Gs/Gi-proteins and were suggested to serve as probes for monitoring receptor-mediated G-protein activation. However, B-GTPγS and B-GppNHp bound to receptor-Gαs/Gαi fusion proteins expressed in Sf9 cell membranes with 1,100- to 5,600-fold- and 17- to 55-fold lower affinity than GTPγS and GppNHp, respectively. The affinity of B-GTPγS/B-GppNHp for Gs/Gi-proteins was considerably lower than the affinity of N-methylanthraniloyl (MANT)-substituted GTP analogs for Gs/Gi-proteins. B-GTPγS/B-GppNHp were much less potent than GTPγS/GppNHp at regulating adenylyl cyclase (AC) via Gs- and Gi-proteins. B-GTPγS/B-GppNHp were similarly efficient as GTPγS/GppNHp at activating Gi, but less efficient at activating Gs. In contrast to MANT-GTPγS/MANT-GppNHp, B-GTPγS/B-GppNHp were inefficient at directly inhibiting AC. In conclusion, the bulky BODIPY group strongly reduces the affinity of GTPγS/GppNHp for G-proteins, limiting the use of B-GTPγS/B-GppNHp as fluorescence probes.
- 14 August 2003
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 368 (3) , 210-215
Low-affinity interactions of BODIPY-FL-GTP?S and BODIPY-FL-GppNHp with Gi- and Gs-proteins
BODIPY-FL-guanosine 5'-[γ-thio]triphosphate (B-GTPγS) and BODIPY-FL-guanosine 5'-[β,γ-imido]triphosphate (B-GppNHp) induce fluorescence changes upon binding to purified Gs/Gi-proteins and were suggested to serve as probes for monitoring receptor-mediated G-protein activation. However, B-GTPγS and B-GppNHp bound to receptor-Gαs/Gαi fusion proteins expressed in Sf9 cell membranes with 1,100- to 5,600-fold- and 17- to 55-fold lower affinity than GTPγS and GppNHp, respectively. The affinity of B-GTPγS/B-GppNHp for Gs/Gi-proteins was considerably lower than the affinity of N-methylanthraniloyl (MANT)-substituted GTP analogs for Gs/Gi-proteins. B-GTPγS/B-GppNHp were much less potent than GTPγS/GppNHp at regulating adenylyl cyclase (AC) via Gs- and Gi-proteins. B-GTPγS/B-GppNHp were similarly efficient as GTPγS/GppNHp at activating Gi, but less efficient at activating Gs. In contrast to MANT-GTPγS/MANT-GppNHp, B-GTPγS/B-GppNHp were inefficient at directly inhibiting AC. In conclusion, the bulky BODIPY group strongly reduces the affinity of GTPγS/GppNHp for G-proteins, limiting the use of B-GTPγS/B-GppNHp as fluorescence probes.
- 1 June 2003
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 305 (3) , 1104-1115
Multiple Differences in Agonist and Antagonist Pharmacology between Human and Guinea Pig Histamine H1-Receptor
Species isoforms of histamine H2-, H3-, and H4-receptors differ in their pharmacological properties. The study aim was to dissect differences between the human H1R (hH1R) and guinea pig H1R (ghH1R). We coexpressed hH1R and gpH1R with regulators of G-protein signaling in Sf9 insect cells and analyzed the GTPase activity of Gq-proteins. Small H1R agonists showed similar effects at hH1R and gpH1R, whereas bulkier 2-phenylhistamines and histaprodifens were up to ∼10-fold more potent at gpH1R than at hH1R. Most 2-phenylhistamines and histaprodifens were more efficacious at gpH1R than at hH1R. Several first-generation H1R antagonists were ∼2-fold, and arpromidine-type H1R antagonists up to ∼10-fold more potent at gpH1R than at hH1R. [3H]Mepyramine competition binding studies confirmed the potency differences of the GTPase studies. Phe-153→Leu-153 or Ile-433→Val-433 exchange in hH1R (hH1R→gpH1R) resulted in poor receptor expression, low [3H]mepyramine affinity, and functional inactivity. The Phe-153→Leu-153/Ile-433→Val-433 double mutant expressed excellently but only partially changed the pharmacological properties of hH1R. Small H1R agonists and 2-phenylhistamines interacted differentially with human and guinea pig H2R in terms of potency and efficacy, respectively. Our data show the following: 1) there are differences in agonist- and antagonist-pharmacology of hH1R and gpH1R encompassing diverse classes of bulky ligands. These differences may be explained by higher conformational flexibility of gpH1R relative to hH1R; 2) Phe-153 and Ile-433 are critical for proper folding and expression of hH1R; and 3) H2R species isoforms distinguish between H1R agonists.
- 1 June 2003
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 305 (3) , 1104-1115
Multiple Differences in Agonist and Antagonist Pharmacology between Human and Guinea Pig Histamine H1-Receptor
Species isoforms of histamine H2-, H3-, and H4-receptors differ in their pharmacological properties. The study aim was to dissect differences between the human H1R (hH1R) and guinea pig H1R (ghH1R). We coexpressed hH1R and gpH1R with regulators of G-protein signaling in Sf9 insect cells and analyzed the GTPase activity of Gq-proteins. Small H1R agonists showed similar effects at hH1R and gpH1R, whereas bulkier 2-phenylhistamines and histaprodifens were up to ∼10-fold more potent at gpH1R than at hH1R. Most 2-phenylhistamines and histaprodifens were more efficacious at gpH1R than at hH1R. Several first-generation H1R antagonists were ∼2-fold, and arpromidine-type H1R antagonists up to ∼10-fold more potent at gpH1R than at hH1R. [3H]Mepyramine competition binding studies confirmed the potency differences of the GTPase studies. Phe-153→Leu-153 or Ile-433→Val-433 exchange in hH1R (hH1R→gpH1R) resulted in poor receptor expression, low [3H]mepyramine affinity, and functional inactivity. The Phe-153→Leu-153/Ile-433→Val-433 double mutant expressed excellently but only partially changed the pharmacological properties of hH1R. Small H1R agonists and 2-phenylhistamines interacted differentially with human and guinea pig H2R in terms of potency and efficacy, respectively. Our data show the following: 1) there are differences in agonist- and antagonist-pharmacology of hH1R and gpH1R encompassing diverse classes of bulky ligands. These differences may be explained by higher conformational flexibility of gpH1R relative to hH1R; 2) Phe-153 and Ile-433 are critical for proper folding and expression of hH1R; and 3) H2R species isoforms distinguish between H1R agonists.
- 1 May 2003
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 367 (5) , 509-515
Functional differences between human formyl peptide receptor isoforms 26, 98, and G6
The formyl peptide receptor (FPR) is expressed in neutrophils, couples to Gi-proteins and activates phospholipase C, chemotaxis and cytotoxic cell functions. FPR isoforms 26, 98, and G6 differ from each other in amino acids 101, 192 and 346 (FPR-26: V101, N192, E346; FPR-98: L101, N192, A346; FPR-G6: V101, K192, A346), but the functional significance of those structural differences is unknown. In order to address this question, we analyzed FPR-26, FPR-98 and FPR-G6 by co-expressing recombinant FLAG epitope-tagged FPRs with the G-protein Giα2β1γ2 in Sf9 insect cells and measured high-affinity agonist binding and guanosine 5'-O-(3-thiotriphosphate) (GTPγS) binding. The B max values of high-affinity agonist binding with FPR-98 and FPR-G6 were much lower than with FPR-26. FPR-98 and FPR-G6 activated considerably fewer Gi-proteins, and were much less constitutively active, than FPR-26. Whereas FPR-26 migrated as a monomer in SDS polyacrylamide electrophoresis, FPR-98 and FPR-G6 migrated as dimers and tetramers. In terms of immunoreactivity, FRP-98 and FPR-G6 were expressed at higher levels than FPR-26. Single amino acid exchanges at positions 101 (V→L), 192 (N→K) and 346 (E→A) in FPR-26 revealed that E346 accounts for FPR-26 migrating as a monomer and the high constitutive activity of FPR-26. The V101L, N192K and E346A exchanges all reduced high-affinity agonist binding and the number of Gi-proteins activated by FPR-26. We conclude that (i) FPR isoforms 98 and G6 exhibit a partial Gi-protein coupling defect relative to FPR-26 and that (ii) E346 critically determines constitutive activity, Gi-protein coupling and physical state of FPR-26.
- 1 May 2003
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 367 (5) , 509-515
Functional differences between human formyl peptide receptor isoforms 26, 98, and G6
The formyl peptide receptor (FPR) is expressed in neutrophils, couples to Gi-proteins and activates phospholipase C, chemotaxis and cytotoxic cell functions. FPR isoforms 26, 98, and G6 differ from each other in amino acids 101, 192 and 346 (FPR-26: V101, N192, E346; FPR-98: L101, N192, A346; FPR-G6: V101, K192, A346), but the functional significance of those structural differences is unknown. In order to address this question, we analyzed FPR-26, FPR-98 and FPR-G6 by co-expressing recombinant FLAG epitope-tagged FPRs with the G-protein Giα2β1γ2 in Sf9 insect cells and measured high-affinity agonist binding and guanosine 5'-O-(3-thiotriphosphate) (GTPγS) binding. The B max values of high-affinity agonist binding with FPR-98 and FPR-G6 were much lower than with FPR-26. FPR-98 and FPR-G6 activated considerably fewer Gi-proteins, and were much less constitutively active, than FPR-26. Whereas FPR-26 migrated as a monomer in SDS polyacrylamide electrophoresis, FPR-98 and FPR-G6 migrated as dimers and tetramers. In terms of immunoreactivity, FRP-98 and FPR-G6 were expressed at higher levels than FPR-26. Single amino acid exchanges at positions 101 (V→L), 192 (N→K) and 346 (E→A) in FPR-26 revealed that E346 accounts for FPR-26 migrating as a monomer and the high constitutive activity of FPR-26. The V101L, N192K and E346A exchanges all reduced high-affinity agonist binding and the number of Gi-proteins activated by FPR-26. We conclude that (i) FPR isoforms 98 and G6 exhibit a partial Gi-protein coupling defect relative to FPR-26 and that (ii) E346 critically determines constitutive activity, Gi-protein coupling and physical state of FPR-26.
- Open Access
- 1 March 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (10) , 7822-7828
GDP Affinity and Order State of the Catalytic Site Are Critical for Function of Xanthine Nucleotide-selective GαsProteins
- 1 March 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (10) , 7822-7828
Open AccessGDP Affinity and Order State of the Catalytic Site Are Critical for Function of Xanthine Nucleotide-selective GαsProteins
- 23 January 2003
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 301 (3) , 693-698
Critical role of N-terminal N-glycosylation for proper folding of the human formyl peptide receptor
- 23 January 2003
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 301 (3) , 693-698
Critical role of N-terminal N-glycosylation for proper folding of the human formyl peptide receptor
- Top Cited Papers
- 1 November 2002
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 366 (5) , 381-416
Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors
The aim of this review is to provide a systematic overview on constitutively active G-protein-coupled receptors (GPCRs), a rapidly evolving area in signal transduction research. We will discuss mechanisms, pharmacological tools and methodological approaches to analyze constitutive activity. The two-state model defines constitutive activity as the ability of a GPCR to undergo agonist-independent isomerization from an inactive (R) state to an active (R*) state. While the two-state model explains basic concepts of constitutive GPCR activity and inverse agonism, there is increasing evidence for multiple active GPCR conformations with distinct biological activities. As a result of constitutive GPCR activity, basal G-protein activity increases. Until now, constitutive activity has been observed for more than 60 wild-type GPCRs from the families 1–3 and from different species including humans and commonly used laboratory animal species. Additionally, several naturally occurring and disease-causing GPCR mutants with increased constitutive activity relative to wild-type GPCRs have been identified. Alternative splicing, RNA editing, polymorphisms within a given species, species variants and coupling to specific G-proteins all modulate the constitutive activity of GPCRs, providing multiple regulatory switches to fine-tune basal cellular activities. The most important pharmacological tools to analyze constitutive activity are inverse agonists and Na+ that stabilize the R state, and pertussis toxin that uncouples GPCRs from Gi/Go-proteins. Constitutive activity is observed at low and high GPCR expression levels, in native systems and in recombinant systems, and has been reported for GPCRs coupled to Gs-, Gi- and Gq-proteins. Constitutive activity of neurotransmitter GPCRs may provide a tonic support for basal neuronal activity. For the majority of GPCRs known to be constitutively active, inverse agonists have already been identified. Inverse agonists may be useful in the treatment of neuropsychiatric and cardiovascular diseases and of diseases caused by constitutively active GPCR mutants.
- 1 November 2002
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 366 (5) , 381-416
Top Cited PapersConstitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors
The aim of this review is to provide a systematic overview on constitutively active G-protein-coupled receptors (GPCRs), a rapidly evolving area in signal transduction research. We will discuss mechanisms, pharmacological tools and methodological approaches to analyze constitutive activity. The two-state model defines constitutive activity as the ability of a GPCR to undergo agonist-independent isomerization from an inactive (R) state to an active (R*) state. While the two-state model explains basic concepts of constitutive GPCR activity and inverse agonism, there is increasing evidence for multiple active GPCR conformations with distinct biological activities. As a result of constitutive GPCR activity, basal G-protein activity increases. Until now, constitutive activity has been observed for more than 60 wild-type GPCRs from the families 1–3 and from different species including humans and commonly used laboratory animal species. Additionally, several naturally occurring and disease-causing GPCR mutants with increased constitutive activity relative to wild-type GPCRs have been identified. Alternative splicing, RNA editing, polymorphisms within a given species, species variants and coupling to specific G-proteins all modulate the constitutive activity of GPCRs, providing multiple regulatory switches to fine-tune basal cellular activities. The most important pharmacological tools to analyze constitutive activity are inverse agonists and Na+ that stabilize the R state, and pertussis toxin that uncouples GPCRs from Gi/Go-proteins. Constitutive activity is observed at low and high GPCR expression levels, in native systems and in recombinant systems, and has been reported for GPCRs coupled to Gs-, Gi- and Gq-proteins. Constitutive activity of neurotransmitter GPCRs may provide a tonic support for basal neuronal activity. For the majority of GPCRs known to be constitutively active, inverse agonists have already been identified. Inverse agonists may be useful in the treatment of neuropsychiatric and cardiovascular diseases and of diseases caused by constitutively active GPCR mutants.
- 8 August 2002
- Published by Elsevier in Biochemical Pharmacology
- Vol. 64 (4) , 583-593
Distinct interactions of Gsα-long, Gsα-short, and Gαolf with GTP, ITP, and XTP
- 8 August 2002
- Published by Elsevier in Biochemical Pharmacology
- Vol. 64 (4) , 583-593
Distinct interactions of Gsα-long, Gsα-short, and Gαolf with GTP, ITP, and XTP